Angiogenesis in tumors has long been a target of cancer therapy, and anti-VEGF antibodies such as Bevacizumab are currently in use in cancer treatment (Abdollahi and Folkman, 2010) . Though anti-VEGF immunotherapy is usually effective as a neo-adjuvant, it often fails when tumors become refractory to continued treatment (Welti et al., 2013) . Mechanisms by which tumor angiogenesis may proceed in the presence of anti-VEGF have been identified. For example, G-CSF produced from tumor and stromal cells, recruits myeloid cells into tumors, promotes their expansion, and activates proangiogenic pathways (Phan et al., 2013) . In this issue of Cell, Croci et al. (2014) identify another mechanism by which galectin-1 specifically promotes tumor progression in anti-VEGF-A refractory tumors.
Galectins belong to a family of mammalian glycan-binding proteins that recognize glycans attached to glycoproteins and glycopipids (Thijssen et al., 2013) . There are 14 human galectins defined by their ability to bind galactose (Gal) residues in glycans, and the inhibition of that binding by lactose. Galectin-1 has a molecular weight of 14.5 kDa and occurs as a dimer. It has a single carbohydrate recognition domain (CRD) and, consequently, each dimer is divalent for glycan binding. Therefore, galectin-1 may crosslink glycans within a glycoprotein or glycans residing on adjacent glycoproteins, either on the same cell or on a neighboring cell. Galectin crosslinking serves to retain glycoproteins on the cell surface, prolonging cell-surface residency of cytokine and growth factor receptors, and thereby affecting signaling strength or duration (Lau et al., 2007; Boscher et al., 2011) .
Rabinovich and colleagues have recently identified roles for galectin-1 in prostate cancer (Laderach et al., 2013) and Kaposi's sarcoma (Croci et al., 2012) . In the case of prostate cancer, galectin-1 is the most highly expressed of ten galectins examined in human prostate cancer cell lines, and expression increases with prostate cancer stage or tumor progression. By contrast, expression of galectin-3, -4, -9, and -12 decreases with prostate tumor progression. Galectin-1 is predominantly expressed at the tumor-vascular interface, and increased expression correlates with increased tumor vascularization. Silencing of galectin-1 in tumor cells reduces tumor angiogenesis in mouse models (Laderach et al., 2013) . A similar role for galectin-1 was observed in Kaposi's sarcomas. In this case, the virus KSHV and hypoxia were shown to induce galectin-1 secretion following upregulation of NFkB. Both hypoxia and galectin-1 then stimulate tumor angiogenesis that enhances tumor growth. Importantly, treatment with an anti-galectin-1 antibody could suppress tumors that had already developed in the mouse (Croci et al., 2012) . In this issue, Croci et al. (2014) provide new mechanistic insights into galectin-1's roles in promoting tumor angiogenesis and progression in anti-VEGF-A refractory tumors.
In sensitive tumor cell lines, growth and angiogenesis are inhibited by anti-VEGF-A treatment, whereas both proliferation and angiogenesis increase in cell lines that are refractory to antibody treatment. Refractory, but not sensitive, tumors secrete increased amounts of galectin-1 during anti-VEGF-A treatment, and this treatment also alters the glycans expressed by endothelial cells (ECs) (their glycophenotype) in refractory tumors. A similar effect on EC glycophenotype is caused by conditioned medium from refractory tumor cells cultured under hypoxic conditions. The alterations induced in the glycans of ECs by these conditions lead to an increase in neutral, complex N-glycans (Figure 1 ). Branched N-glycans that contain repeating units of Gal-GlcNAc (polylactosamine) and terminate in Gal are preferred ligands of galectin-1 (Stowell et al., 2008) . Therefore, conditions in which VEGF is inactivated by antibody treatment, and the tumor microenvironment is hypoxic, cause tumor cells to secrete galectin-1 and ECs to generate neutral, complex N-glycans that bind galectin-1 (Figure 1) . VEGFR2 has many potential complex N-glycan sites (Figure 1 ). Site-directed mutagenesis identifies the N-glycans on IgG domains 3, 4, and 7 as necessary for galectin-1 to bind optimally to VEGFR2. Functionality of galectin-1 binding has been shown by knockdown of galectin-1 in tumor cells. Galectin-1 removal reduces tumor cell growth and angiogenesis, but only for refractory tumors treated with anti-VEGF-A. ECs respond to hypoxia and proinflammatory cytokines including FGF2, TGFb, and IL10 by reducing sialic acid residues on N-glycans, and increasing the expression of branched, complex N-glycans containing polylactosamine extensions (Figure 1) .
MGAT5, a glycosyltranferase that initiates a key branch of complex N-glycans, promotes galectin-1 binding, whereas galectin-1 does not bind to glycans capped with a2,6-linked sialic acid, added by the sialyltransferase ST6GAL1 (Figure 1) . In an elegant set of experiments, Croci et al. convert refractory tumors to sensitivity to anti-VEGF-A by establishing them in an Mgat5 knockout mouse. In the absence of MGAT5, N-glycans on VEGFR2 bind insufficient galectin-1 to promote angiogenesis and thus tumor growth decreases. Conversely, when tumors sensitive to anti-VEGF-A treatment are grown in mice lacking ST6Gal1, they are converted to refractory tumors because N-glycans on VEGFR2 lack a2,6-linked sialic acid caps and bind galectin-1 much better, thereby promoting angiogenesis and tumor growth.
Both galectin-1 and VEGF cause increased phosphorylation of VEGFR2, Akt, and ERK1/2. Tube formation and EC binding induced by galectin-1 can be inhibited by anti-VEGFR2, but not anti-VEGFR1, VEGFR3, or several integrin antibodies. In addition, galectin-1, which does not inhibit VEGF binding, causes VEGFR2 to segregate into clusters on the cell surface, and this does not occur following knockdown of MGAT5. Finally, compared to VEGF that stimulates endocytosis of VEGFR2 within 5-10 min, galectin-1 significantly prolongs the cell-surface residency time of VEGFR2. Therefore, within tumors treated with anti-VEGF-A, hypoxia, and proinflammatory cytokines in the microenvironment cause tumor cells to secrete galectin-1 and ECs to enhance their galectin-1-binding abilities, respectively, leading to galectin-1-induced angiogenesis that promotes tumor progression. The importance of galectin-1 to this mechanism has been demonstrated by the fact that secretion of galectin-1, but not galectin-3 or -8 angiogenic galectins, is induced, and treatment with a galectin-1-neutralizing antibody specifically prevents galectin-1-induced angiogenesis. Mice treated with anti-galectin-1 exhibit greatly reduced angiogenesis and tumor growth in anti-VEGF-A refractory, and to some extent in anti-VEGF-A-sensitive, tumors. Thus, anti-galectin-1 treatment should be considered as a strategy to inhibit tumor angiogenesis in combination with anti-VEGF-A treatment.
